Safepeer not updating
The only known local adverse reaction is skin irritation (common in application to the face and intertriginous areas).
This spectrum of side effects is partly canceled when calcipotriol and betamethasone are combined.
Search terms were as follows: “betamethasone calcipotriol” and either “two-compound” or “fixed combination”. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial.
Seventy references were found and checked for relevance.
Both calcipotriol and betamethasone exert their action on these pathological features. Treatment adherence and real-life effectiveness of topical therapy in patients with mild or moderate psoriasis: uptake of scientific evidence in clinical practice and dermatologists’ preferences for alternative treatment options. 2015; 150(1):19–26de Kerkhof PCM, Wasel N, Kragballe K, Cambazard F, Murray S.
The combined medical therapy with different mechanisms of action and safety profiles enhances efficacy. A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity. 2005;210(4):294–299de Kerkhof P, de Peuter R, Ryttov J, Jansen JP. This work is published and licensed by Dove Medical Press Limited.
Accepted for publication 28 April 2015 Published 8 June 2015 Volume 2015:5 Pages 97—107 DOI https://doi.org/10.2147/PTT.
Calcipotriol acts on vitamin D receptors as an analog to correct epidermal proliferation, abnormal keratinization, and angiogenesis.Especially, topical corticosteroids and vitamin D analogs are effective agents in mild-to-moderate plaque-type psoriasis.Their mode of action, the pathophysiological rationale for the treatment of psoriasis, as well as their described adverse effects lead to the idea of combining calcipotriol and betamethasone as a promising treatment modality.analyzed the results of 2,058 patients from among five parallel-group studies to find proof of the efficacy of the two-compound product versus placebo in reduction of Psoriasis Area and Severity Index (PASI) score. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Calcipotriol/betamethasone products were also compared to corticosteroids. Kragballe K, Hoffmann V, Ortonne JP, Tan J, Nordin P, Segaert S.